Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus Penpulimab in advanced pancreatic cancer
NCT04803851Phase 2Unknown
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2021
- Primary completion
- Feb 2024
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of anlotinib and penpulimab in pancreatic cancer (PC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Disease Control Rate at 6 weeks. Status: unknown.
02
Drugs
anlotinibpenpulimab
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04803851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803851.